Cannabis Science Inc (OTCMKTS:CBIS) saw a massive surge of volume and price starting Monday when the entire pot stock sector got a huge boost after GW Pharmaceuticals announced positive Phase 3 trial data for its drug Epidiolex, for the treatment of Dravet syndrome.
The news is a game changer for all pot stocks especially CBIS with several irons of their own in the fire as it proves that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications.
Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:
The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”
The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”
To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On March 14 CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.
The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.
CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.
CBIS CEO Raymond C. Dabney said “We couldn’t be happier with GW Pharmaceutical’s success today. As these positive results continue to be found in pivotal studies, public and regulatory perception opens up to the effectiveness of CBD in treating disease, both physically and mentally.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $13 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is currently testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. The news from GW is a game changer for all pot stocks especially CBIS with several of its own irons in the oven as it proves that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media so this is a great place to be when pot stocks heat up. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.